The ATTRibute-CM study's open-label extension showed that acoramidis effectively lowers all-cause mortality in patients with ...

Findings from a prospective phase 2 clinical trial show that isatuximab (Sarclisa), an anti-CD38 monoclonal antibody, is an effective and well-tolerated treatment for patients with relapsed and/or ...

ATTR-CM is a progressive, fatal disease that presents as an infiltrative, restrictive cardiomyopathy resulting in heart failure ...

The FDA has granted Fast Track designation to VS-041, an investigational therapy for the treatment of heart failure with preserved ejection fraction.

In an update on nex-z's phase I study, the CRISPR-Cas9 gene therapy stayed the course out to 3 years in an initial 36-person cohort with transthyretin amyloid cardiomyopathy (ATTR-CM). Serum TTR ...

Data presented at this year’s American Heart Association Scientific Sessions in New Orleans underline rapid advancements in ...

The combination therapy improved LVEF, quality of life, clinical outcomes, and more, but implementation questions remain.

One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of ...

Three Late Breaking Science Presentations from MAPLE-HCM Provide Additional Data Including Responder Analyses, Patient Reported Outcomes, and ...

The Cardiac Biomarkers Market offers opportunities in developing high-sensitivity assays, point-of-care solutions for decentralized care, and AI-supported diagnostics. Growth is driven by rising ...

Frailty and accelerated aging are common in pulmonary hypertension, with frailty an independent risk factor for early death.

New findings reveal sotagliflozin's benefits for patients with heart failure with preserved ejection fraction without ...